Relation of Severe Coronary Artery Narrowing to Insulin or Thiazolidinedione Use in Patients With Type 2 Diabetes Mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study)

American Journal of Cardiology

Volumn 104, Issue 1, 2009, Pages 52-58

  Pop Busui, Rodica ^a   Lombardero, Manuel ^b   Lavis, Victor ^d   Forker, Alan ^e   Green, Jennifer ^f   Korytkowski, Mary ^c   Sobel, Burton E ^g   Jones, Teresa L Z ^h  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF VERMONT   (United States)

^h NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SULFONYLUREA;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CROSS-SECTIONAL STUDY; DIABETES CONTROL; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FIBRINOGEN BLOOD LEVEL; GLYCEMIC CONTROL; HEART INDEX; HEART INFARCTION; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; RISK FACTOR; RISK REDUCTION; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, BALLOON; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THIAZOLIDINEDIONES;

EID: 67649354215     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.02.046     Document Type: Article

References (28)

1. Brooks M.M., Frye R.L., Genuth S., Detre K.M., Nesto R., Sobel B.E., Kelsey S.F., and Orchard T.J. Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am J Cardiol 97 suppl (2006) 9G-19G
2. Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the BARI 2D trial. Am Heart J 156 (2008) 528-536
3. Graham M.M., Faris P.D., Ghali W.A., Galbraith P.D., Norris C.M., Badry J.T., Mitchell L.B., Curtis M.J., and Knudtson M.L. Validation of three myocardial jeopardy scores in a population-based cardiac catheterization cohort. Am Heart J 142 (2001) 254-261
4. Ortiz-Perez J.T., Meyers S.N., Lee D.C., Kansal P., Klocke F.J., Holly T.A., Davidson C.J., Bonow R.O., and Wu E. Angiographic estimates of myocardium at risk during acute myocardial infarction: validation study using cardiac magnetic resonance imaging. Eur Heart J 28 (2007) 1750-1758
5. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 30 suppl 1 (2007) S4-S41
6. Feldman E.L., Stevens M.J., Thomas P.K., Brown M.B., Canal N., and Greene D.A. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 17 (1994) 1281-1289
7. Evans J.M., Ogston S.A., Emslie-Smith A., and Morris A.D. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49 (2006) 930-936
8. Fisman E.Z., Tenenbaum A., Benderly M., Goldbourt U., Behar S., and Motro M. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. Cardiology 91 (1999) 195-202
9. Johnson J.A., Majumdar S.R., Simpson S.H., and Toth E.L. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25 (2002) 2244-2248
10. Ravipati G., Aronow W.S., Ahn C., Sujata K., Saulle L.N., Channamsetty V., and Weiss M.B. Association of diet alone, insulin, sulfonylureas, metformin, and thiazolidinediones with the severity of coronary artery disease in patients with diabetes mellitus. Am J Ther 13 (2006) 400-403
11. Kornowski R., Mintz G.S., Lansky A.J., Hong M.K., Kent K.M., Pichard A.D., Satler L.F., Popma J.J., Bucher T.A., and Leon M.B. Paradoxic decreases in atherosclerotic plaque mass in insulin-treated diabetic patients. Am J Cardiol 81 (1998) 1298-1304
12. Fuster V., Moreno P.R., Fayad Z.A., Corti R., and Badimon J.J. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 46 (2005) 937-954
13. Libby P. Atherosclerosis: disease biology affecting the coronary vasculature. Am J Cardiol 98 suppl (2006) 3Q-9Q
14. Jensen L.O., Thayssen P., Mintz G.S., Egede R., Maeng M., Junker A., Galloee A., Christiansen E.H., Pedersen K.E., Hansen H.S., and Hansen K.N. Comparison of intravascular ultrasound and angiographic assessment of coronary reference segment size in patients with type 2 diabetes mellitus. Am J Cardiol 101 (2008) 590-595
15. Nicholls S.J., Tuzcu E.M., Kalidindi S., Wolski K., Moon K.W., Sipahi I., Schoenhagen P., and Nissen S.E. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol 52 (2008) 255-262
16. Schukro C., Syeda B., Yahya N., Gessl A., Holy E.W., Pichler P., Derntl M., and Glogar D. Volumetric intravascular ultrasound imaging to illustrate the extent of coronary plaque burden in type 2 diabetic patients. J Diabetes Complications 21 (2007) 381-386
17. Gonzalez M.A., and Selwyn A.P. Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med 115 suppl 8A (2003) 99S-106S
18. Derosa G., Fogari E., Cicero A.F., D'Angelo A., Ciccarelli L., Piccinni M.N., Pricolo F., Salvadeo S.A., Gravina A., Ferrari I., and Fogari R. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res 30 (2007) 387-394
19. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107 (2003) 391-397
20. Libby P., and Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol 99 suppl (2007) 27B-40B
21. Sjoholm A., and Nystrom T. Endothelial inflammation in insulin resistance. Lancet 365 (2005) 610-612
22. Chen K., Chen J., Li D., Zhang X., and Mehta J.L. Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone. Hypertension 44 (2004) 655-661
23. Bennett S.M., Agrawal A., Elasha H., Heise M., Jones N.P., Walker M., and Wilding J.P. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med 21 (2004) 415-422
24. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., Tan M.H., Khan M.A., Perez A.T., and Jacober S.J. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
25. Mazzone T., Meyer P.M., Feinstein S.B., Davidson M.H., Kondos G.T., D'Agostino Sr. R.B., Perez A., Provost J.C., and Haffner S.M. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296 (2006) 2572-2581
26. Stocker D.J., Taylor A.J., Langley R.W., Jezior M.R., and Vigersky R.A. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J 153 suppl (2007) e1-e6
27. Nissen S.E., Nicholls S.J., Wolski K., Nesto R., Kupfer S., Perez A., Jure H., De Larochelliere R., Staniloae C.S., Mavromatis K., Saw J., Hu B., Lincoff A.M., and Tuzcu E.M. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299 (2008) 1561-1573
28. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471